Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience.
about
Pirarubicin inhibits multidrug-resistant osteosarcoma cell proliferation through induction of G2/M phase cell cycle arrest.Osteosarcoma Overview.Biomarkers in Osteosarcoma.What are the factors that affect survival and relapse after local recurrence of osteosarcoma?Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children's Oncology GroupLiposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases.Survival of pediatric patients after relapsed osteosarcoma: the St. Jude Children's Research Hospital experience.Pirarubicin-based chemotherapy displayed better clinical outcomes and lower toxicity than did doxorubicin-based chemotherapy in the treatment of non-metastatic extremity osteosarcoma.Perioperative chemotherapy in the treatment of osteosarcoma: a 26-year single institution review.Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments.Follow-up practices for high-grade extremity Osteosarcoma.Fibroblast growth factor receptor 1 promotes MG63 cell proliferation and is associated with increased expression of cyclin-dependent kinase 1 in osteosarcomaLiposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma.The Current and Future Therapies for Human Osteosarcoma.Chemotherapy resistance in osteosarcoma: current challenges and future directions.p53 overexpression increases chemosensitivity in multidrug-resistant osteosarcoma cell lines.Surgical resection of relapse may improve postrelapse survival of patients with localized osteosarcoma.Should contralateral exploratory thoracotomy be advocated for children with osteosarcoma and early unilateral pulmonary metastases?Current status and perspectives regarding the treatment of osteo-sarcoma: chemotherapyMolecular mechanisms of chemoresistance in osteosarcoma (Review).Long non-coding RNAs in osteosarcoma.Mifamurtide for the treatment of nonmetastatic osteosarcomaReview of management issues in relapsed osteosarcoma.Osteosarcoma with metastasis at initial diagnosis: Current outcomes and prognostic factors in the context of a comprehensive cancer center.P-glycoprotein binds to ezrin at amino acid residues 149-242 in the FERM domain and plays a key role in the multidrug resistance of human osteosarcoma.MMP9 mediates MICA shedding in human osteosarcomas.Oligo-Recurrence of Osteosarcoma Patients: Treatment Strategies for Pulmonary Metastases.Letter to the editor: Surgical resection of relapse may improve postrelapse survival of patients with localized osteosarcoma.Tumor self-seeding by circulating tumor cells in nude mouse models of human osteosarcoma and a preliminary study of its mechanisms.Radiofrequency ablation for the treatment of recurrent bone and soft-tissue sarcomas in non-surgical candidates.Analysis of prognostic factors in 333 Chinese patients with high-grade osteosarcoma treated by multidisciplinary combined therapy.The long non-coding RNA PARTICLE is associated with WWOX and the absence of FRA16D breakage in osteosarcoma patients.Tumor Talk and Child Well-Being: Perceptions of "Good" and "Bad" News Among Parents of Children With Advanced Cancer.Matrix metallopeptidase 9 targeted by hsa-miR-494 promotes silybin-inhibited osteosarcoma.Team Approach: Osteosarcoma of the Distal Part of the Femur in Adolescents.Identifying osteosarcoma metastasis associated genes by weighted gene co-expression network analysis (WGCNA).Hesperidin exhibits and antitumor effects in human osteosarcoma MG-63 cells and xenograft mice models via inhibition of cell migration and invasion, cell cycle arrest and induction of mitochondrial-mediated apoptosisBlocked autophagy by miR-101 enhances osteosarcoma cell chemosensitivity in vitro
P2860
Q33567522-4A11E9CB-3127-4593-A9C1-E24314FE30F4Q33725511-F23EF49E-FDF2-4F48-A294-05F1EE271181Q33929072-21FC26B9-CCFE-43D4-9789-76DACEA25C7EQ34161337-A033EC88-AB8F-4C89-A00C-B8EDDEB6C3C2Q34337703-0E9C2B6A-EF04-4C98-B13F-AD5FEDA26FC7Q34588395-3719F005-E114-4572-93E4-00294F9B0FF7Q34754346-928B7613-CB22-442A-A125-3F3249CA7EE1Q34991299-115A61E7-C647-4E1B-A9B7-4A48A5D350E0Q35848126-27ABB004-17BC-4FEF-9361-BE4EAC55A08AQ35945493-3D9FB02B-2BBE-41E9-B4D5-E79DD09F848CQ36011314-5904B5D3-320F-4AFD-BA0B-662C04624DE0Q36390216-1033AF1F-CE13-4A53-A2FA-0065143250A8Q36512499-2F16940D-8AE2-4441-80B5-13DDA693D672Q36514299-F177A451-5A3F-4B79-B535-07CA7C21C03DQ36532115-6531D510-20CB-4ED0-9785-77EAA453A3B1Q36568079-3069A713-CA52-4683-915A-C51FE92F2BF6Q36585861-5B937179-F999-4C19-9392-069367B02F82Q36822729-F6CE5D61-71F3-41F9-987A-F32D87A3F85AQ37265109-EFA19CDE-4783-4646-A22D-3F86CE1591A9Q37719938-60AED39F-8B3F-448E-9F28-2ADB2F524B00Q37746352-8CE2C874-DC92-4FBD-AF57-DBF326E265DBQ37827876-E082C76A-1F3B-49EA-9014-C2EB7F0410CFQ38168922-9752BD42-4111-40AF-94BB-85CC7567672EQ39155292-57D2703F-0BA1-4CDC-A294-DD30945B43A6Q39502697-3E9E8100-37A4-4CB1-9001-A5980DD0EE50Q39622355-11020E9D-C860-40B3-BF9E-804E36F87791Q41655793-F252B0F6-D5DA-4276-B1B8-175B7909094FQ42872562-4499B57D-46F7-4155-B4BB-AF271225F91BQ44090164-6A570AE2-51CA-4DB4-8DA6-0FDFA0B41D49Q44582916-6E604BE1-6195-47F9-8F24-18BB6BFE39EAQ44826148-61DFB65D-D7E3-4E11-8BA7-1E5A8AAE4313Q47103604-D693DFC7-1D8D-4533-87DB-61992864E875Q47591586-61EAFBD1-843F-4FEB-A57C-9EA13EA30A3BQ47606157-A64333D0-1F81-4371-939A-DBDA2F494ED8Q49572718-4D8386C4-7A30-4E54-9637-6AF3FABABD3FQ55514730-6E68D1D6-6559-4E5E-886D-AA93EC7682C1Q58572834-B1E7E73F-4E1E-4A9A-8C0D-6A8645E72D14Q59100821-921BB6C7-5D9E-40F1-9455-FDB89DE62AFC
P2860
Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Treatment of osteosarcoma at f ...... ring Cancer Center experience.
@ast
Treatment of osteosarcoma at f ...... ring Cancer Center experience.
@en
type
label
Treatment of osteosarcoma at f ...... ring Cancer Center experience.
@ast
Treatment of osteosarcoma at f ...... ring Cancer Center experience.
@en
prefLabel
Treatment of osteosarcoma at f ...... ring Cancer Center experience.
@ast
Treatment of osteosarcoma at f ...... ring Cancer Center experience.
@en
P2093
P50
P356
P1433
P1476
Treatment of osteosarcoma at f ...... ering Cancer Center experience
@en
P2093
Andrew G Huvos
John H Healey
Leonard H Wexler
Michael P LaQuaglia
Pamela R Merola
P304
P356
10.1002/CNCR.21417
P407
P577
2005-11-01T00:00:00Z